Updates are available Correction dated 2018-06-19

Article History

First Online: 21 May 2018

Change Date: 19 June 2018

Change Type: Correction

Change Details: The original version of this article contains errors in Table 3. “At least 1 project/publication in the year” and “> 1 publication per year” have been switched under the titles of “Clinical Track” and “Physician-Scientist track”.

Compliance with Ethics Guidelines

:

: Anum Saeed and Kaustubh Dabhadkar declare no conflict of interest. Salim S. Virani receives an honorarium from the American College of Cardiology as Associate Editor for Innovations for ExternalRef removed. Peter H. Jones has been a scientific consultant to Amgen and to Sanofi/Regeneron the past 12 months. Vijay Nambi was on a regional advisory board for Sanofi and is named on provisional patent no. 61721475 entitled “Biomarkers to Improve Prediction of Heart Failure Risk” filed by Baylor College of Medicine and Roche. Christie M. Ballantyne has received grant/research support (all paid to institution, not individual) from Abbott Diagnostic, Amarin, Amgen, Eli Lilly, Esperion, Ionis, Novartis, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo, NIH, AHA, and ADA; has been a consultant for Abbott Diagnostics, Amarin, Amgen, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Esperion, Ionis, Matinas BioPharma Inc., Merck, Novartis, Pfizer, Regeneron, Roche Diagnostic, and Sanofi-Synthelabo; and is named on provisional patent no. 61721475 entitled “Biomarkers to Improve Prediction of Heart Failure Risk” filed by Baylor College of Medicine and Roche.

: This article does not contain any studies with human or animal subjects performed by any of the authors.